Legal & General Group Plc Has $94.13 Million Stock Position in Insulet Corporation $PODD

Legal & General Group Plc decreased its position in Insulet Corporation (NASDAQ:PODD) by 2.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 331,147 shares of the medical instruments supplier’s stock after selling 6,914 shares during the period. Legal & General Group Plc’s holdings in Insulet were worth $94,125,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in PODD. Swedbank AB boosted its stake in shares of Insulet by 11.0% during the 4th quarter. Swedbank AB now owns 85,988 shares of the medical instruments supplier’s stock worth $24,441,000 after buying an additional 8,500 shares during the last quarter. Jefferies Financial Group Inc. raised its holdings in shares of Insulet by 132.0% in the 4th quarter. Jefferies Financial Group Inc. now owns 13,361 shares of the medical instruments supplier’s stock valued at $3,798,000 after purchasing an additional 7,602 shares during the period. MQS Management LLC bought a new position in Insulet in the 4th quarter valued at about $285,000. Global Retirement Partners LLC raised its holdings in Insulet by 57.0% in the 4th quarter. Global Retirement Partners LLC now owns 391 shares of the medical instruments supplier’s stock valued at $111,000 after acquiring an additional 142 shares during the period. Finally, Mach 1 Financial Group LLC bought a new position in Insulet in the 4th quarter valued at about $898,000.

Insulet Trading Down 2.3%

PODD opened at $142.65 on Friday. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The company has a fifty day moving average of $185.26 and a 200-day moving average of $246.01. The stock has a market cap of $9.88 billion, a PE ratio of 33.17, a price-to-earnings-growth ratio of 1.15 and a beta of 1.20.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the prior year, the company posted $1.02 earnings per share. Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, sell-side analysts predict that Insulet Corporation will post 6.43 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on PODD shares. Wells Fargo & Company decreased their target price on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Jefferies Financial Group dropped their price objective on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Citigroup dropped their price objective on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday. Sanford C. Bernstein dropped their price target on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $280.00 price target on shares of Insulet in a research note on Wednesday. Twenty-one research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $252.04.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: William Blair initiated coverage on Insulet with an Outperform rating, arguing that the valuation gap is hard to justify, which adds another bullish analyst view on the name.
• Positive Sentiment: RBC reaffirmed its Outperform rating and kept a $280 price target, signaling confidence in Insulet’s longer-term growth potential.
• Positive Sentiment: Zacks highlighted continued momentum in Omnipod 5, pointing to the company’s Q1 beat, raised 2026 outlook, and expanding global rollout as key growth drivers.
• Neutral Sentiment: Insulet announced it will present at the William Blair 46th Annual Growth Stock Conference on June 3, which is a routine investor-relations update and could attract attention but is not a direct business catalyst. Article: Insulet to Participate in William Blair 46th Annual Growth Stock Conference
• Neutral Sentiment: Citigroup cut its price target on Insulet to $165 from $175 while maintaining a Neutral rating, reflecting a more cautious near-term view despite still implying upside from current levels.
• Neutral Sentiment: Zacks also noted a Hold rating with a $163 target, suggesting analysts see decent growth but limited near-term room for a stronger rerating.
• Negative Sentiment: A U.S. appeals court overturned Insulet’s $452 million trade-secret verdict against EOFlow, removing a potential legal win and likely weighing on sentiment around the company’s competitive and litigation outlook. Article: US court overturns Insulet’s $452 mln insulin-pump trade secret verdict against EOFlow

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.